Floatz logo

Ketoconazole

Bone Metastases

National Cancer Institute (NCI)Phase 2Dormant
CCC
51/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
36/ 100
Competitive Position
89/ 100

Competitive context

34 Active assets in the Bone Metastases cohort.

Asset / SponsorPhaseRating
Zoledronate
Kelly Fitzgerald, MD
Phase 4BBB
Ibandronate
Kelly Fitzgerald, MD
Phase 4BBB
Denosumab
Kelly Fitzgerald, MD
Phase 4BBB
RADIUM RA-223
University of California, San Francisco
Phase 3BB
Zometa
Sun Yat-sen University
Phase 4BB

View all 50 →

Same molecule, other indications

Ketoconazole is also rated in:

breast cancerDormant
B
Indicative ·
57 / 100
View asset →
prostate cancerDormant
B
Indicative ·
57 / 100
View asset →
prostate adenocarcinomaDormant
CCC
Indicative ·
55 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →